Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04569058 · ClinicalTrials.gov registry record · NA

Transcranial Photobiomodulation Therapy for the Treatment of Autistic Traits in Children and Adolescents With ADHD

A NA study of Autism and Attention Deficit Hyperactivity Disorder, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
38
Enrollment target
1
Study location

NCT04569058: Completed NA study of Autism and Attention Deficit Hyperactivity Disorder, sponsored by Massachusetts General Hospital.

NCT04569058 is a NA study of Autism and Attention Deficit Hyperactivity Disorder that has completed, run by Massachusetts General Hospital. The registered enrollment target is 38 participants, below the 183-participant average among 104 other Autism trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04569058, a NA study of Autism and Attention Deficit Hyperactivity Disorder, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

An open label trial to assess the safety and efficacy of transcranial photobiomodulation (tPBM) in improving autistic traits in ADHD youth.

Primary Outcome

The ADHD-SCL is a clinician-rated scale used to determine the number and severity of ADHD symptoms that a patient may be experiencing. It consists of 18 items that rated on a scale from 0 (no symptoms) to 3 (severe symptoms). The item scores are combined into a total score which ranges from 0 to 54, where a higher score indicates a worse outcome. The outcome reported reflects the change from baseline in ADHD-SCL scores and negative scores represent improvement (i.e., decrease in severity from ba

Interventions

  • DEVICE Transcranial Photobiomodulation

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2021-01-14
Est. Completion 2024-10-31
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT04569058 record still lists

NCT04569058 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 183-participant average among 104 other Autism trials with a reported enrollment target (79% lower).

The record links to 2 conditions, with Autism appearing as the primary indexed condition, and to 1 intervention - of which Transcranial Photobiomodulation is the first listed.

NCT04569058 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04569058 about?

NCT04569058 is a clinical study titled "Transcranial Photobiomodulation Therapy for the Treatment of Autistic Traits in Children and Adolescents With ADHD". An open label trial to assess the safety and efficacy of transcranial photobiomodulation (tPBM) in improving autistic traits in ADHD youth.

What is the current status of trial NCT04569058?

This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2021-01-14. Estimated completion is 2024-10-31.

What conditions does trial NCT04569058 study?

This clinical trial studies the following conditions: Autism, Attention Deficit Hyperactivity Disorder.

What interventions are being tested in trial NCT04569058?

The interventions under investigation include: Transcranial Photobiomodulation (DEVICE).

Who is sponsoring clinical trial NCT04569058?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04569058 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04569058's enrollment target sits among peer trials

38 71st of 104 higher than 34 of 104 other Autism trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04569058, the US trial registry maintained by the National Library of Medicine. NCT04569058 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.